Atara Biotherapeutics names Brian Cherry to board of directors

Atara Biotherapeutics Inc

Atara Biotherapeutics Inc

ATRA

0.00
  • Atara Biotherapeutics announced board changes, with Carol Gallagher departing after 13 years as a director.
  • Brian Cherry appointed to the board; former Managing Partner at Oak Hill Capital with 25+ years in buyout and growth equity investing.
  • Cherry has led healthcare and other sector investments totaling more than $25 billion in enterprise value, bringing capital allocation and M&A experience.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atara Biotherapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606121600BIZWIRE_USPR_____20260612_BW613594) on June 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.